Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTME study of TIL-based adoptive cell therapy with nivolumab and later PEG-IFNα in metastatic melanoma
NL-OMON59247Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of GC101 TIL + pembrolizumab, nivolumab and pegylated interferon alpha in melanoma (2 arms), sponsored by Leiden University Medical Center. Primary endpoints: Safety and toxicity of TIL + nivolumab and Safety and toxicity of TIL + nivolumab + peginterferon alfa. Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON59247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59247.